Sponsor

Infectious Diseases Research Collaboration, Uganda

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Infectious Diseases Research Collaboration, Uganda appears in 23 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials23
Recruiting shown3
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

23 shown
Integrating Hypertension Management in DSD for HIVNCT06366386 · lead sponsor · 2024-06-15
UNKNOWN
Integration of Hypertension Management in HIV Care in UgandaNCT05609513 · lead sponsor · 2023-02-06
COMPLETED
Mindfulness and Acceptance Based Therapy for Adolescents Living With HIVNCT05010317 · lead sponsor · 2022-11-01
COMPLETED
Acceptability, Feasibility and Effectiveness of Online Peer Support Group for ART Adherence Among YouthNCT05688709 · lead sponsor · 2022-08-01
UNKNOWN
Leveraging the HIV Platform for Hypertension Control in Uganda (INTEGRATED HIV/HTN) STUDYNCT04624061 · lead sponsor · 2020-11-16
UNKNOWN
Peer-led Dynamic Choice HIV Prevention for Women: The Peer-led DCP Randomized TrialNCT07787988 · collaborator · 2026-10-01
RECRUITING
IBIS Megastudy of Interventions to Encourage HIV RetestingNCT06971367 · collaborator · 2025-12-09
RECRUITING
HIV Prevention and Care Interventions for Youth in UgandaNCT06474364 · collaborator · 2024-08-05
RECRUITING
Peer-led Dynamic Choice HIV Prevention for Women: The Peer-led DCP Pilot StudyNCT07298785 · collaborator · 2026-01-27
COMPLETED
IBIS Megastudy- PilotNCT06785103 · collaborator · 2025-03-27
TERMINATED
The Outreach and Prevention at ALcohol Venues in East Africa Study (OPAL-East Africa- Aim 2) (OPAL-Aim 2)NCT06036238 · collaborator · 2024-05-17
ACTIVE_NOT_RECRUITING
The Outreach and Prevention at ALcohol Venues in East Africa Study (OPAL-East Africa- Aim 1)NCT05862857 · collaborator · 2023-07-13
COMPLETED
SEARCH SAPPHIRE Phase BNCT05768763 · collaborator · 2023-03-28
COMPLETED
SEARCH CAB LA Dynamic Choice HIV Prevention Study ExtensionNCT05549726 · collaborator · 2023-01-02
COMPLETED
SEARCH SAPPHIRE Phase A: A Multisectoral Strategy to Address Persistent Drivers of the HIV Epidemic in East AfricaNCT04810650 · collaborator · 2021-04-15
COMPLETED
TB Screening Improves Preventive Therapy UptakeNCT04557176 · collaborator · 2020-11-16
ACTIVE_NOT_RECRUITING
Optimizing HIV Virologic Outcomes for Pregnant Women in UgandaNCT04122144 · collaborator · 2019-09-19
UNKNOWN
Strategic Antiretroviral Therapy and HIV Testing for Youth in Rural AfricaNCT03848728 · collaborator · 2019-03-14
COMPLETED
Rapid HIV Viral Load Monitoring in High Risk Patients In UgandaNCT03553693 · collaborator · 2018-07-16
COMPLETED
Drinkers' Intervention to Prevent Tuberculosis (DIPT Study)NCT03492216 · collaborator · 2018-04-16
COMPLETED
Extended Duration Artemether-lumefantrine Treatment for Malaria in ChildrenNCT03453840 · collaborator · 2018-02-21
COMPLETED
Sustainable East Africa Research in Community HealthNCT01864603 · collaborator · 2013-04-01
COMPLETED
Early HIV Therapy in Patients With High CD4 Cell CountsNCT01479634 · collaborator · 2011-10-01
COMPLETED

Drugs studied in this sponsor's trials

1 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Infectious Diseases Research Collaboration, Uganda as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Sponsor roles

collaborator18
lead sponsor5
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.